Bioasis Technologies Inc. Announces Stock Option Grants
08 août 2022 17h47 HE
|
Bioasis Technologies Inc.
NEW HAVEN, Conn., Aug. 08, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company...
Bioasis Announces Filing of Its First Quarter Financial Statements and MD&A
29 juil. 2022 17h23 HE
|
Bioasis Technologies Inc.
NEW HAVEN, Conn., July 29, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary...
Bioasis Acquires Phase 2 Ready Rare Orphan EGF Assets
16 juin 2022 07h50 HE
|
Bioasis Technologies Inc.
Phase 2 ready assets transform Bioasis into a clinical stage company with a multi-asset pipeline focused on rare and orphan drug indications Unique approach to neurodegeneration targeting...
Bioasis Announces Filing of Its Fourth Quarter and Fiscal Year-End Financial Statements and MD&A
14 juin 2022 18h51 HE
|
Bioasis Technologies Inc.
NEW HAVEN, Conn., June 14, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI.V; OTCQB:BIOAF), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3 ™...
Bioasis and Neuramedy Enter into Research Collaboration and License Agreement
10 mai 2022 17h30 HE
|
Bioasis Technologies Inc.
NEW HAVEN, CONN., U.S.A., May 10, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC.. (TSXV:BTI.V; OTCQB:BIOAF), (the “Company or “Bioasis”) a biopharmaceutical company developing its proprietary...
Bioasis Enters Into Research Collaboration With Janssen
11 avr. 2022 16h05 HE
|
Bioasis Technologies Inc.
NEW HAVEN, CONN., U.S.A., April 11, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI.V; OTCQB:BIOAF), (the “Company or “Bioasis”), a biopharmaceutical company developing its proprietary...
Bioasis to Attend and Present at Upcoming Industry Conference
09 mars 2022 16h30 HE
|
Bioasis Technologies Inc.
NEW HAVEN, Conn., March 09, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3™...
Bioasis Announces $200,000 Non-Brokered Private Placement
17 févr. 2022 16h05 HE
|
Bioasis Technologies Inc.
NEW HAVEN, Conn., Feb. 17, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3™...
Bioasis Announces Filing of Its Quarter and Financial Statements and MD&A for the Period Ending November 30, 2021
20 janv. 2022 17h01 HE
|
Bioasis Technologies Inc.
NEW HAVEN, Conn., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3™...
Bioasis Announces Annual General Meeting Results
16 déc. 2021 16h31 HE
|
Bioasis Technologies Inc.
NEW HAVEN, Conn., Dec. 16, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3™...